This study provides a comprehensive review of both established and emerging prognostic markers in chronic lymphocytic leukemia (CLL), and their role in predicting disease, treatment response, and ...

HCL uniformly harbors a BRAF mutation that is not present in other B-cell malignancies. Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disorder that responds to several highly ...

That superhero is a gene called TP53, and for decades scientists have known it as the “guardian of the genome.” In a healthy ...

An interview with Dr. Valerie de Haas from Princess Máxima Center for Pediatric Oncology in the Netherlands on "Initial Diagnostic Workup of Acute Leukemia: ASCO Clinical Practice Guideline ...

A pioneering study offers new insights into how leukemia begins—and could open the door to predicting and preventing the disease. A new study led by Children’s Hospital Los Angeles (CHLA) has linked ...

Hoping to bring more immunotherapy-based options to patients with acute myeloid leukemia (AML), researchers have identified potential targets across the heterogenous disease. 1 By analyzing the ...

Acute lymphoblastic leukemia (ALL) is a type of blood cancer that predominantly affects children. Thanks to improvements in treatments, survival rates for ALL have risen dramatically, now exceeding 90 ...

Immunophenotyping helps doctors diagnose and classify specific blood cell cancers, like leukemia and lymphoma, as well as other diseases. Immunophenotyping is a lab test doctors use to identify and ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short ...

Shedding light on what determines how cells become what they are meant to be—nerves, bone, muscles, etc.—can also help researchers understand how diseases develop when these biological programs break ...

A graphic showing, top to bottom, how DNA aptamers target two specific markers on a leukemia stem cell’s surface, enter the cell and deliver anticancer drugs, resulting in death of the cancer cell.